A practical reference on hGH fragment: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-06-13 and is reviewed periodically as new material appears.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
== History == The president was only the head of state under previous constitutions but under current constitution, it is both the head of state and head of government. The position of president as a head of state was created in 1948, with the adoption of the Burmese Declaration of Independence from the United Kingdom. Since then, eleven people have officially held the office. The office of the president was abolished twice when direct military rule was imposed by the coups of 1962 and 1988. In the parliamentary system practised in 1948–1962, the "President" was the ceremonial head of state while prime minister is the actual head of government. The first president of 1948–1952 period was titled "Provisional President" because he had been elected by the Constituent Assembly of Burma, not by the Union Parliament. The first "President" elected by the Union Parliament took office in 1952. The 1962 coup d'etat abolished both offices of the President and the Prime Minister, and the junta leader assumed the powers of both head of state and head of government as the "Chairman" of "Revolutionary Council" and "Revolutionary Government". The 1974 Constitution reintroduced the office with the title "President of the Republic", to be ex officio held by the "Chairman of the Council of State". In fact, the chairmanship of the Council of State is the main title of the head of state which was used in promulgation of legislations and orders while the presidency is more like a ceremonial title to represent the country.
=== Contaminant removal === Graphene oxide is non-toxic and biodegradable. Its surface is covered with epoxy, hydroxyl, and carboxyl groups that interact with cations and anions. It is soluble in water and forms stable colloid suspensions in other liquids because it is amphiphilic (able to mix with water or oil). Dispersed in liquids it shows excellent sorption capacities. It can remove copper, cobalt, cadmium, arsenate, and organic solvents.
7 June Rishi Sunak is criticised for leaving the D-day commemorations early to return to the UK to work on the election campaign. He says: "On reflection, it was a mistake not to stay in France longer – and I apologise." Data produced by Zoopla indicates that rents for new properties rose by 6.6% in the year to April 2024, but that this was the slowest rise in two and a half years. 9 June – Restrictions on carrying more than 100ml of liquid in hand luggage are temporarily reintroduced at some regional airports in order to "enable further improvements to be made" to new checkpoint systems. Those affected are Newcastle, Leeds Bradford, London City, Aberdeen, Southend and Teesside. 10 June – Twenty buildings across the UK are vandalised as part of a co-ordinated attack by Palestine Action, a pro-Palestine group. 11 June A High Court judge rules that convicted sex offender Gary Glitter must pay more than £500,000 to a victim he abused when she was 12 years old. A 28-year-old man is arrested on suspicion of public order offences after objects are thrown at Nigel Farage during a campaign tour in Barnsley. Rishi Sunak unveils the Conservative Party's general election manifesto, which includes a further cut in National Insurance, a halving of immigration, and several new housing policies. Former UN secretary general Ban Ki-moon is awarded the inaugural King Charles III Harmony Award during a ceremony held at St James's Palace. Two animal rights protestors vandalise a portrait of Charles III at London's Philip Mould Gallery by covering it with posters.
The outer layer or tunica fibrosa is composed of densely packed connective-tissue which connects with fibers from the spongy intermediate layer where elastic fibers, as well as nerves, reside. The nerves send signals to the muscles as well as the epithelial layers. Lastly, the epithelium or tunica propria encloses the gland.
A myocardial infarction requires immediate medical attention. Treatment aims to preserve as much heart muscle as possible, and to prevent further complications. Treatment depends on whether the myocardial infarction is a STEMI or NSTEMI. Treatment in general aims to unblock blood vessels, reduce blood clot enlargement, reduce ischemia, and modify risk factors with the aim of preventing future MIs. In addition, the main treatment for myocardial infarctions with ECG evidence of ST elevation (STEMI) include thrombolysis or percutaneous coronary intervention, although PCI is also ideally conducted within 1–3 days for NSTEMI. In addition to clinical judgement, risk stratification may be used to guide treatment, such as with the TIMI and GRACE scoring systems.
Sources: en.wikipedia.org
Little Feat co-founder and pianist Bill Payne, known for his contributions to many of the band's early studio albums, was selected to temporarily fill in for Allison in his absence. The Doobies and Michael McDonald were the featured musical guests on The Tonight Show Starring Jimmy Fallon in 2015, where they performed a medley of "Long Train Runnin'" and "Takin' It to the Streets". The band also performed a web-exclusive performance of "What a Fool Believes" that was made available on The Tonight Show's website. In October 2015 Payne officially took over Guy Allison's duties as the Doobies' keyboardist, whilst remaining an active member of Little Feat. The next month, the Doobie Brothers together with Journey launched a tour featuring Dave Mason. The pairing with Journey continued in 2016, beginning at the Irvine Meadows Amphitheatre and concluding when the Doobies and Journey joined the Steve Miller Band and Santana at AT&T Park. They also appeared at Warren Haynes Christmas Jam in 2015, however Johnston did not appear due to knee surgery. In 2016 the Doobie Brothers signed under new management with Irving Azoff. Tony Pia left in the summer, leaving Ed Toth as the band's sole drummer. In 2017 the Doobie Brothers toured with Chicago once again, beginning at the Concord Pavilion and wrapping up in Virginia Beach. They also appeared with the Eagles and Steely Dan at the Classic concerts for two weekends in 2017. These concerts took place at Dodger Stadium (Classic West) and at Citi Field (Classic East).
All K vitamins are similar in structure: they share a "quinone" ring, but differ in the length and degree of saturation of the carbon tail and the number of repeating isoprene units in the "side chain". The number of repeating units is indicated in the name of the particular menaquinone (e.g., MK-4 means that four isoprene units are repeated in the carbon tail). The chain length influences lipid solubility and thus transport to different target tissues.
*) The Bezirk Karl-Marx-Stadt was named Bezirk Chemnitz for a short period at both the beginning and end of the republic, corresponding with the renaming and reversal of the city Chemnitz. Between 10 May 1953 and 30 May 1990, both the city and Bezirk were named Karl-Marx-Stadt. **) East Berlin was not officially a Bezirk, but from 1961 was provided with the function of one.
=== 2007 === Davey made his AFL debut in the opening round of the 2007 season, making an immediate impression and played in every game until Round 14. He has featured several times amongst the Bombers' best including an outstanding ANZAC Day match. In his first five AFL matches he earned five “goal of the year” nominations including two on ANZAC Day. Davey became known for his explosive speed. He has been known to take 2.75 secs to run from 0–20 metres. This is thought to be the fastest in the league, even more than speedster Chris Judd. From debut, Davey became one of the shortest players in the AFL. He quickly earned a cult following at Essendon, gaining the nickname is "Froggy", due to his appearance. During the round 14 game against Geelong, he suffered a broken arm when crashed into while on the ground by Kane Tenace. The injury forced Davey to miss the rest of the season, and Essendon's form slumped during the period that he was on the sidelines, eventually missing the finals. At the end of the 2007 AFL season, Alwyn won the AFL Army Award, recognising players who produce act(s) of bravery or selflessness to promote the cause of his team, during a game for his smother and 2nd and 3rd efforts against Hawthorn in round 6. He had 3 of the final 6 nominations in the award.
Sources: en.wikipedia.org
=== Using cyclopentadienyl reagents === A variety of reagents have been developed that transfer Cp to metals. Once popular was thallium cyclopentadienide. It reacts with metal halides to give thallium chloride, which is poorly soluble, and the cyclopentadienyl complex. Trialkyltin derivatives of Cp− have also been used. Many other methods have been developed. Chromocene can be prepared from chromium hexacarbonyl by direct reaction with cyclopentadiene in the presence of diethylamine; in this case, the formal deprotonation of the cyclopentadiene is followed by reduction of the resulting protons to hydrogen gas, facilitating the oxidation of the metal centre.
corrects this dilution effect by multiplying the fraction of the susceptible population over the total population. It corrects the effective/transmissible interaction between an infectious person and the rest of the community when many of the interaction is immune in the middle to late stages of the disease spreading. Thus, when
==== Dust-transfer technique ==== The scientists Emily Craig and Randall Bresee have attempted to recreate the likenesses of the shroud through the dust-transfer technique, which could have been done by medieval arts. They first did a carbon-dust drawing of a Jesus-like face (using collagen dust) on a newsprint made from wood pulp (which is similar to 13th- and 14th-century paper). They next placed the drawing on a table and covered it with a piece of linen. They then pressed the linen against the newsprint by firmly rubbing with the flat side of a wooden spoon. By doing this they managed to create a reddish-brown image with a lifelike positive likeness of a person, a three-dimensional image and no sign of brush strokes.
=== H2-receptor antagonists and proton-pump inhibitors === Gastric acid is needed to release vitamin B12 from protein for absorption. Reduced secretion of gastric acid and pepsin, from the use of H2 blocker or proton-pump inhibitor (PPI) drugs, can reduce the absorption of protein-bound (dietary) vitamin B12, although not of supplemental vitamin B12. H2-receptor antagonist examples include cimetidine, famotidine, nizatidine, and ranitidine. PPIs examples include omeprazole, lansoprazole, rabeprazole, pantoprazole, and esomeprazole. Clinically significant vitamin B12 deficiency and megaloblastic anemia are unlikely, unless these drug therapies are prolonged for two or more years, or if in addition, the person's dietary intake is below recommended levels. Symptomatic vitamin deficiency is more likely if the person is rendered achlorhydric (a complete absence of gastric acid secretion), which occurs more frequently with proton pump inhibitors than H2 blockers.
AN has the highest mortality rate of any psychological disorder. The mortality rate is 11 to 12 times greater than in the general population, and the suicide risk is 56 times higher. Half of women with AN achieve a full recovery, while an additional 20–30% may partially recover. Not all people with anorexia recover completely: about 20% develop anorexia nervosa as a chronic disorder. If anorexia nervosa is not treated, serious complications such as heart conditions and kidney failure can arise and eventually lead to death. The average number of years from onset to remission of AN is seven for women and three for men. After ten to fifteen years, 70% of people no longer meet the diagnostic criteria, but many still continue to have eating-related problems. People who have autism recover more slowly, probably due to autism's effects on thinking patterns, such as reduced cognitive flexibility. Alexithymia (inability to identify and describe one's own emotions) influences treatment outcome. Recovery is also viewed on a spectrum rather than black and white. According to the Morgan-Russell criteria, individuals can have a good, intermediate, or poor outcome. Even when a person is classified as having a "good" outcome, weight only has to be within 15% of average, and normal menstruation must be present in females. The good outcome also excludes psychological health. Recovery for people with anorexia nervosa is undeniably positive, but recovery does not mean a return to normal.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.